
Per Backman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/579513/publications.pdf Version: 2024-02-01



DED RACKMAN

#	Article	IF	CITATIONS
1	Inhaled Medicines: Past, Present, and Future. Pharmacological Reviews, 2022, 74, 48-118.	16.0	44
2	iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System. Molecular Pharmaceutics, 2022, 19, 2032-2039.	4.6	13
3	iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes. Molecular Pharmaceutics, 2022, 19, 2040-2047.	4.6	12
4	Physiologically-based pharmacokinetic modeling after drug inhalation. , 2021, , 319-358.		2
5	Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs. European Journal of Pharmaceutical Sciences, 2018, 113, 41-52.	4.0	57
6	Pulmonary absorption – estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 124, 1-12.	4.3	31
7	Ranking in Vitro Dissolution of Inhaled Micronized Drug Powders including a Candidate Drug with Two Different Particle Sizes. Molecular Pharmaceutics, 2018, 15, 5319-5326.	4.6	18
8	Pharmacokinetics of the Inhaled Selective Glucocorticoid Receptor Modulator AZD5423 Following Inhalation Using Different Devices. AAPS Journal, 2017, 19, 865-874.	4.4	12
9	Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs. Journal of Pharmaceutical Sciences, 2017, 106, 2234-2244.	3.3	22
10	Predicting Exposure After Oral Inhalation of the Selective Glucocorticoid Receptor Modulator, AZD5423, Based on Dose, Deposition Pattern, and Mechanistic Modeling of Pulmonary Disposition. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, 30, 108-117.	1.4	30
11	A Proposed <i>In Vitro</i> Method to Assess Effects of Inhaled Particles on Lung Surfactant Function. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 306-311.	2.9	21
12	Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD. AAPS Open, 2016, 2, .	1.3	73
13	In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches. AAPS Journal, 2015, 17, 837-852.	4.4	48
14	Hydrophobic Homopolymers of Native α-L-Amino Acids at the Air–Water Interface: A Study by Circular Dichroism Spectroscopy, Atomic Force Microscopy, and Surface Balance Experiments. Journal of Colloid and Interface Science, 2001, 242, 346-353.	9.4	4
15	Microcalorimetric studies on the complex formation between cellobiohydrolase I (CBH I) from Trichoderma reesei and the (R)- and (S)-enantiomers of the β-receptor blocking agent alprenolol. Thermochimica Acta, 2000, 356, 153-158.	2.7	13
16	A microcalorimetric method to study the activation of murine peritoneal macrophages. Thermochimica Acta, 1996, 275, 109-115.	2.7	1
17	A microcalorimetric study of human erythrocytes in stirred buffer suspensions. Thermochimica Acta, 1992, 205, 87-97.	2.7	6
18	Microcalorimetric evaluation of the effects of methotrexate and 6-thioguanine on sensitive T-lymphoma cells and on a methotrexate-resistant subline. Cell Biophysics, 1992, 20, 111-123.	0.4	14

#	Article	IF	CITATIONS
19	Effects of pH-variations on the kinetics of growth and energy metabolism in cultured T-lymphoma cells: A microcalorimetric study. Journal of Cellular Physiology, 1992, 150, 99-103.	4.1	31
20	Cell growth experiments using a microcalorimetric vessel equipped with oxygen and pH electrodes. Journal of Proteomics, 1991, 23, 283-293.	2.4	50